{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-000837","form_type":"8-K","ticker":"IMCR","cik":"0001671927","company_name":"Immunocore Holdings plc","filed_at":"2025-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.387895+00:00","generated_at":"2026-05-28T05:11:32.705140+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Immunocore reports ~$820M cash; three Phase 3 melanoma trials; new autoimmune candidate","bullets":["Preliminary cash ~$820M as of Dec 31, 2024; Pharmakon loan prepaid in full.","Three Phase 3 trials enrolling in melanoma (TEBE-AM, PRISM-MEL-301, ATOM); first topline data expected 2026.","New autoimmune candidate IMC-U120AI (CD1a x PD1) for atopic dermatitis; CTA planned 2026.","Initial HIV Phase 1 multiple ascending dose data for IMC-M113V expected Q1 2025.","Travis Coy appointed EVP, CFO and Head of Corporate Development (ex-Eli Lilly)."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-000837","json":"https://secwatch.observer/filing/0001140361-25-000837.json","markdown":"https://secwatch.observer/filing/0001140361-25-000837.md","text":"https://secwatch.observer/filing/0001140361-25-000837.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671927/000114036125000837/0001140361-25-000837-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671927/000114036125000837/ef20041400_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T05:11:32.705140+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}